Protagenic Therapeutics Stock Forward View - Relative Strength Index
| PTIX Stock | USD 0.49 0.00 0.000002% |
Forecasting Protagenic Therapeutics stock price is inherently uncertain, but structured approaches to analyzing market sentiment can improve the odds. This module tracks the noise around Protagenic Therapeutics to identify periods where price and perception diverge.
Using the latest data, the 14-period RSI for Protagenic Therapeutics stands at 41, indicating moderately negative momentum. Momentum below the midline but above oversold territory places Protagenic Therapeutics in a wait-and-see zone for many technical traders.Momentum
Sell Extended
Oversold | Overbought |
Wall Street Target Price 4 |
This section relates Protagenic Therapeutics headline activity to recent price behavior and peer context.
Protagenic Therapeutics after-hype prediction price | $ 0.49 |
Sentiment indicators are one input among forecasting models, technical signals, analyst estimates, earnings data, and momentum measures.
Protagenic | Build AI portfolio with Protagenic Stock |
Protagenic Therapeutics Additional Predictive Modules
Most predictive techniques to examine Protagenic price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Protagenic using various technical indicators. When you analyze Protagenic charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Check Protagenic Therapeutics Volatility | Backtest Protagenic Therapeutics | Information Ratio |
Protagenic Therapeutics Trading Date Momentum
| On March 16 2026 Protagenic Therapeutics was traded for 0.49 at the closing time. The top price for the day was 0.52 and the lowest listed price was 0.49 . There was no trading activity during the period 0.0. Lack of trading volume on March 16, 2026 did not cause price change. The trading delta at closing time against the current closing price is 0.00% . |
| Compare Protagenic Therapeutics to competition |
Other Forecasting Options for Protagenic Therapeutics
Regardless of investment experience, understanding Protagenic Therapeutics' price movement is essential for anyone considering a position in Protagenic. Price charts for Protagenic Stock are often filled with noise that can lead to poor investment choices if not properly filtered.Protagenic Therapeutics Related Equities
The following equities are related to Protagenic Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Protagenic Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Protagenic Therapeutics Market Strength Events
Market strength indicators for Protagenic Therapeutics give investors insight into the stock's responsiveness to broader market forces. Tracking these indicators helps investors make informed timing decisions and identify periods where trading Protagenic Therapeutics is likely to be most rewarding.
| Accumulation Distribution | 0.0577 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.51 | |||
| Day Typical Price | 0.5 | |||
| Market Facilitation Index | 0.03 | |||
| Price Action Indicator | -0.01 | |||
| Relative Strength Index | 41.16 |
Protagenic Therapeutics Risk Indicators
A thorough review of Protagenic Therapeutics' risk indicators is an important first step in forecasting its price and managing investment exposure. This analysis helps investors determine the appropriate level of risk to accept when holding Protagenic Therapeutics'.
| Mean Deviation | 8.67 | |||
| Standard Deviation | 12.22 | |||
| Variance | 149.36 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Protagenic Therapeutics
Coverage intensity for Protagenic Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. A disciplined read of coverage helps investors separate durable relevance from temporary noise.
Contributor Headline
Latest Perspective From Macroaxis
Protagenic Therapeutics Short Properties
A short-interest review of Protagenic Therapeutics helps investors understand whether skepticism in the market is becoming more influential. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 1.9 M | |
| Cash And Short Term Investments | 2.2 M |
More Resources for Protagenic Stock Analysis
A comprehensive view of Protagenic Therapeutics starts with financial statements and ratio context. Ratio analysis helps investors evaluate Protagenic Therapeutics Stock operating efficiency and financial trajectory. Highlighted below are reports that provide context for Protagenic Therapeutics Stock:Use Historical Fundamental Analysis of Protagenic Therapeutics to cross-verify projections for Protagenic Therapeutics. The historical view provides additional context. New to investing in Protagenic Stock? Start with our How to Invest in Protagenic Stock guide for a step-by-step overview.With Protagenic Therapeutics showing P/E 9.43 and ROE -5.13%, investors get more value when this analysis is combined with the diversification and construction tools below. That discounted valuation invites deeper analysis through the value and risk tools below. You can also try the Portfolio Holdings module to check your current holdings and cash position to determine if your portfolio needs rebalancing.
Investors evaluate Protagenic Therapeutics using market value and book value, each describing different facets of the business. Protagenic Therapeutics' market capitalization is 944.67 K. The 3.35 P/B ratio shows Protagenic Therapeutics carries a substantial premium over its balance-sheet equity. Enterprise value stands at 2.22 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Protagenic Therapeutics' value from its trading price, which are computed with different methods. For Protagenic Therapeutics, key inputs include a P/E ratio of 9.43, a P/B ratio of 3.35, and ROE of -5.13%. In practice, Protagenic Therapeutics price is set by the continuous auction process on its listing exchange.